Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 19/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502009 | 1.00 | AR (0.41) | ARPGRCA12CA1CA2 | |
| SCHEMBL324217 | 0.85 | AR (0.47) | ARPGR | |
| SCHEMBL1259671 | 0.84 | AR (0.46) | ARPGR | |
| SCHEMBL28392970 | 0.84 | AR (0.50) | ARPGR | |
| SCHEMBL203731 | 0.82 | AR (0.44) | ARPGR | |
| SCHEMBL12495047 | 0.79 | TRPV4 (0.42) | ARPGR | |
| SCHEMBL202518 | 0.78 | AR (0.46) | ARPGR | |
| SCHEMBL26118753 | 0.78 | AR (0.38) | ARPGRCA12CA1CA2 | |
| SCHEMBL202385 | 0.78 | AR (0.41) | ARPGR | |
| SCHEMBL9460722 | 0.78 | MEN1 (0.41) | CA12CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12610730-B2 | Metal complex and light emitting device | CITY UNIVERSITY OF HONG KONG (HK) | 2026-04-21 | — | — | US | disclosed |
| US-12479807-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| CN-114315834-B | Imidazolone derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| EP-4137491-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| EP-4137491-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| US-20230006152-A1 | METAL COMPLEX AND LIGHT EMITTING DEVICE | CITY UNIVERSITY OF HONG KONG (HK) | 2023-01-05 | — | — | US | disclosed |
| US-20220235018-A1 | METHODS USING HDAC11 INHIBITORS | Valo Health, LLC | 2022-07-28 | — | — | US | disclosed |
| US-11345672-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20180127386-A1 | METHODS USING HDAC11 INHIBITORS | VALO EARLY DISCOVERY, INC. | 2018-05-10 | — | — | US | disclosed |
| WO-2018075959-A1 | METHODS USING HDAC11 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| WO-2018075959-A1 | METHODS USING HDAC11 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| WO-2009097996-A1 | USE OF SUBSTITUTED PHENYLIMIDAZOLIDINES FOR PRODUCING MEDICAMENTS FOR TREATING METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| CN-1044234-C | New substituted phenylimidazolidines, their preparation process, their use as medicaments and the pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1999-07-21 | — | — | CN | disclosed |
| US-RE35956-E | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1998-11-10 | — | — | US | disclosed |
| US-5627201-A | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1997-05-06 | — | — | US | disclosed |
| US-5411981-A | Phenylimidazolidines having antiandrogenic activity | ROUSSEL UCLAF (FR) | 1995-05-02 | — | — | US | disclosed |
| EP-0580459-A1 | Substituted Phenylimidazolidins, process for their preparation, their use as medicaments and their pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1994-01-26 | — | — | EP | disclosed |
| CN-1081182-A | The phenylimidazolidines, of new replacement, its preparation method, as the purposes of medicine and contain their pharmaceutical composition | ROUSSEL UCLAF (FR) | 1994-01-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345672-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | AR 2064/4885PGR 3642/4885CA12 1912/4885 |
| US-20180127386-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | AR 2064/4885PGR 3642/4885CA12 1912/4885 |
| US-20230006152-A1 | METAL COMPLEX AND LIGHT EMITTING DEVICE | OCIAD1, OCIAD2, OPRD1 | AR 2930/4885PGR 2689/4885CA12 2123/4885 |
| US-12610730-B2 | Metal complex and light emitting device | OPRD1, OCIAD2, ORC3 | AR 3577/4885PGR 1026/4885CA12 3950/4885 |
| US-12479807-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | AR 2064/4885PGR 3642/4885CA12 1912/4885 |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | SYMPK, PAICS, CYP2C9 | AR 1176/4885PGR 1382/4885CA12 2071/4885 |
| US-20220235018-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | AR 2064/4885PGR 3642/4885CA12 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.